2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
9
Motor Activity
9
Breast Neoplasms
7
Malnutrition
5
Head and Neck Neoplasms
4
Pancreatic Neoplasms
3
Laryngeal Neoplasms
3
Colonic Neoplasms
3
Stomach Neoplasms
2
Prostatic Neoplasms
2
Pharyngeal Neoplasms
2
Obesity
2
Lung Neoplasms
2
Liver Neoplasms
2
Diabetes Mellitus, Type 2
2
Colorectal Neoplasms
2
Ascites
2
Weight Loss
1
Undefined
1
Skin Neoplasms
1
Sarcopenia
1
Rectal Neoplasms
1
Psychological Well-Being
1
Pancreatitis, Chronic
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Neurotoxicity Syndromes
1
Mouth Neoplasms
1
Lung Diseases
1
Liver Diseases
1
Interventions
Sorafenib
5
Blood Specimen Collection
4
lenvatinib
3
sintilimab
2
pembrolizumab
2
ledipasvir, sofosbuvir drug combination
2
halofantrine
2
camrelizumab
2
atezolizumab
2
Liver Transplantation
2
Immunotherapy
2
Control Groups
2
Bevacizumab
2
Antibodies
2
veliparib
1
trifluridine tipiracil drug combination
1
trametinib
1
toripalimab
1
titanium silicide
1
tislelizumab
1
rubitecan
1
repotrectinib
1
pevonedistat
1
ozanimod
1
linifanib
1
genexol-PM
1
gadolinium ethoxybenzyl DTPA
1
fluorocholine
1
fisogatinib
1
ficlatuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liver Diseases
×
Nutritional Status
×
Clear all
NCT04666558
2022-10-04
PiONEeR
University of Alberta
Phase NA
Completed
216 enrolled